Dana-Farber Cancer Institute and Eli Lilly and Company (NYSE: LLY) today announced a multiyear collaboration to research new medicines under development to fight cancer.
“This is a new kind of collaboration between a comprehensive cancer center and a large pharmaceutical company,” said Barrett J. Rollins, MD, PhD, chief scientific officer at Dana-Farber. “Under this agreement, Lilly can access the expertise within Dana-Farber to help it develop multiple preclinical and clinical compounds. Together, we can bring compounds to clinical trials and to FDA approval quickly and efficiently, and thus benefit our patient population.”
Per the agreement, over the course of three years Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds. Dana-Farber researchers and Lilly scientists will work collaboratively on preclinical and clinical studies, molecular studies of patient samples and the design and conduct of clinical trials, which may result in important advances in the science of cancer care. The agreement also allows Dana-Farber scientists to conduct independent studies on select Lilly compounds. Following research conducted at Dana-Farber, the evaluated compounds will still be fully owned by Lilly. Financial terms of the agreement are not being disclosed.
“Working together is the most powerful approach in fighting cancer,” said Richard Gaynor, M.D., senior vice president, product development and medical affairs, Lilly Oncology. “Lilly’s partnership with Dana-Farber demonstrates an open, collaborative research approach—uniting the expertise of the pharmaceutical industry with that of a leading academic cancer research institution.”
For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to firstname.lastname@example.org.
Appointments and Second Opinions
For adults: 877-442-3324For children: 888-733-4662